Oppenheimer Reiterates Outperform and PT of $100 on Stericycle

Oppenheimer reiterated its Outperform rating on Stericycle SRCL. At the same time, Oppenheimer left its price target on the company's stock unchanged at $100. In a research report published today, Oppenheimer states, "With medwaste remaining solid, a 70% win of a sizable medical/solid waste HCA (HCA, O) contract, and some potential 1Q11 spillover support to RMS (recall), we anticipate SRCL will deliver upon 2Q11 EPS consensus. We expect mid-teens+ revenue growth, slightly offset by margin dilution resulting from initial HWS acquisition expenses. SRCL is -6% since its 1Q11 release, creating an intriguing entry point. We reiterate our 2011E/2012E EPS, Outperform rating and $100 target." In today's trading, Stericycle lost 1.66% of its value to trade around $86.66.